Piper Sandler Upgrades Health Catalyst to Overweight, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Jessica Tassan has upgraded Health Catalyst (HCAT) from Neutral to Overweight, while also lowering the price target from $12 to $11.
November 13, 2023 | 9:54 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Health Catalyst has been upgraded by Piper Sandler from Neutral to Overweight, indicating a positive outlook on the stock, despite a reduced price target from $12 to $11.
The upgrade to Overweight suggests that Piper Sandler believes Health Catalyst has strong potential for growth or recovery, outweighing the negative sentiment that might be implied by the lowered price target. This could lead to increased investor confidence and a potential short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100